Biopharma · FDA Approvals · Stock

AVIR Atea Pharmaceuticals

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection …

Assets on file: bemnifosbuvir/ruzasvir

Start live analysis of AVIR Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for AVIR, including recently decided ones.

December 2026

Dec 2026

~ Dec 2026

AVIRAtea Pharmaceuticals

bemnifosbuvir/ruzasvir: Phase 3 trial NCT07037277 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for AVIR, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 29, 2026

03:24 PM

AVIRAtea Pharmaceuticals

bemnifosbuvir/ruzasvir · NCT06868264 registry update

status: ACTIVE_NOT_RECRUITING → COMPLETED; primary_completion: 2026-09 → 2026-06-18; completion: 2026-12 → 2026-09-09; enrollment: 880 → 940

Trial registry changeClinicalTrials.gov Open record

Aug 12, 2026

08:15 PM

AVIRAtea Pharmaceuticals

Atea AVIR: C-BEYOND Phase 3 met primary/secondary endpoints for BEM/RZR in HCV

The document reports that the Phase 3 C-BEYOND trial met its primary endpoint of statistical non-inferiority versus SOF/VEL in the mITT population (93.9% vs 94.8% SVR) and all secondary endpoints, including the per-protocol analysis. The 8-week BEM/RZR regimen in non-cirrhotic patients achieved 93.5% SVR, supporting a potential best-in-class profile with shorter duration, low drug-drug interaction risk, and no food effect. NDA submission is now guided for Q2 2027 pending C-FORWARD results.

Topline resultsSEC 8-K Open record1 update

Jun 25, 2026

11:00 AM

AVIRAtea Pharmaceuticals

Atea completes enrollment in Phase 3 C-FORWARD HCV trial

Atea has completed enrollment of more than 880 treatment-naïve HCV patients in the global Phase 3 C-FORWARD trial. Topline results are now guided for around year-end 2026, following the earlier C-BEYOND readout expected mid-year 2026. The trial compares the BEM/RZR regimen head-to-head against sofosbuvir/velpatasvir outside North America.

Trial registry changeCompany press release